| 0.9538 0.098 (11.43%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.15 | 1-year : | 1.34 |
| Resists | First : | 0.98 | Second : | 1.15 |
| Pivot price | 0.84 |
|||
| Supports | First : | 0.78 | Second : | 0.65 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 0.82 |
| MA(100) : | 0.76  |
MA(250) : | 1.03 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.3 |
D(3) : | 76.6 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 2.25 | Low : | 0.49 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CTOR ] has closed below upper band by 14.4%. Bollinger Bands are 30.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.98 - 0.99 | 0.99 - 0.99 |
| Low: | 0.84 - 0.85 | 0.85 - 0.85 |
| Close: | 0.95 - 0.95 | 0.95 - 0.96 |
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Fri, 04 Sep 2026
CTXR Stock Price, Quote & Chart - ChartMill
Mon, 17 Aug 2026
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance
Sat, 15 Aug 2026
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st
Fri, 14 Aug 2026
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Fri, 14 Aug 2026
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Fri, 14 Aug 2026
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 106 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 77.5 (%) |
| Held by Institutions | 15.2 (%) |
| Shares Short | 452 (K) |
| Shares Short P.Month | 365 (K) |
| EPS | -0.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | -595.6 % |
| Return on Assets (ttm) | -29.2 % |
| Return on Equity (ttm) | -126.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.99 |
| PEG Ratio | 0 |
| Price to Book value | 2.5 |
| Price to Sales | 14.18 |
| Price to Cash Flow | -5.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|